


**U04** The Krstenansky lab at the KGI School of Pharmacy and Health

Sciences generated this monograph using synthesized material



### 1. GENERAL INFORMATION

IUPAC Name: CAS#:	N-(( <i>1R</i> ,2 <i>R</i> )-2-(dimethylamino)cyclohexyl)-4-trifluoromethyl-N- methylbenzamide 67579-38-8 (base)	
Synonyms:	U04	
Source:	Synthesized Material Lot# JLK008-134-U04	
Appearance:	White Crystals	
$UV_{max}$ (nm):	Not Determined	

### 2. CHEMICAL AND PHYSICAL DATA

#### **2.1 CHEMICAL DATA**

Form	Chemical Formula	Molecular Weight	Melting Point (°C)
Base	$C_{17}H_{23}F_3N_2O$	329.18	91.2 <u>+</u> 0.75



# 3. QUALITATIVE DATA


#### **3.1 NUCLEAR MAGNETIC RESONANCE**

*Sample Preparation:* Dilute analyte to ~5 mg/mL in deuterated chloroform (CDCl<sub>3</sub>) + TMS.

Instrument:400 MHz NMR spectrometerParameters:Spectral width: 6410.3 Hz containing -3 ppm through 13 ppmPulse angle:90°Delay between pulses:30 seconds

**U04** 

<sup>1</sup>H NMR: U04; Lot JLK008-134-U04; CDCl<sub>3</sub> + TMS; 400 MHz





### **U04**

The Krstenansky lab at the KGI School of Pharmacy and Health Sciences generated this monograph using synthesized material

### **3.2 GAS CHROMATOGRAPHY/MASS SPECTROMETRY**

Sample Preparation: Dilute analyte ~ 1 mg/mL in methanol

Instrument:	Shimadzu gas chromatograph operated in split mode with MS detector	
Column:	Rtx5MS (a DB-5 equivalent); 30m x 0.25 mm x 0.25 µm	
Carrier Gas:	Helium at 1 mL/min	
Temperatures:	Injector: 280°C	
	MSD transfer line: 280°C	
	MS Source: 200°C	
	Oven program:	
	1) 90°C initial temperature for 2.0 min	
	2) Ramp to 300°C at 14°C/min	
	3) Hold final temperature for 10.0 min	
Injection Parameters:	Split Ratio = 1:15, 1 $\mu$ L injected	
MS Parameters:	Mass scan range: 34-550 amu Threshold: 100 Tune file: 050218_Tune.qgt Acquisition mode: scan	
<b>Retention Time:</b>	13.20 min	
<ol> <li>C Relative (riterisity (%)) industratinutinutinutinutinutinutinutinutinutinu</li></ol>	EI Mass Spectrum: U04; Lot JLK008-134-U04 $F_{3}C + H_{N+} + H_{N+}$ $F_{3}C + H_{N+} + H_{$	
70 Tarihan 65 Tarihan 60 Tarihan 55 Tarihan	Chemical Formula: C <sub>17</sub> H <sub>24</sub> F <sub>3</sub> N <sub>2</sub> O <sup>+</sup> Exact Mass: 329.18352	

220

240

160 180 200

320 m/z

260 280 300

42.05

EI+

40

58.05 71.10

60

80

124.15

120

110.10

100

145.05

126.10

140

172.95

15

10


5



## **U04**

The Krstenansky lab at the KGI School of Pharmacy and Health Sciences generated this monograph using synthesized material

### Zoomed view (84.10 and 125.15 are truncated in this view)






## 3.3 INFRARED SPECTROSCOPY (FTIR)

Instrument:	FTIR with ZnSe ATR attachment (1 bounce)	
Scan Parameters:	Number of scans: 4	
	Number of background scans: 4	
	Resolution: 4 cm <sup>-1</sup>	
	Sample gain: 8	

Aperture: 150


FTIR ATR (ZnSe, 1 Bounce): U04; Lot JLK008-134-U04





# **U04**

The Krstenansky lab at the KGI School of Pharmacy and Health Sciences generated this monograph using synthesized material






### **3.4 RAMAN SPECTROSCOPY**

Instrument:	Rigaku Progeny 1064
Scan Parameters:	Power (mW): 350
	Exposure (ms): 1000
	Averages: 30
	Threshold: 0.80

Raman (1064 nm): U04; Lot JLK008-134-U04

**U04** 







### 4. ADDITIONAL RESOURCES

ANALGESIC N-(2-AMINOCYCLOALIPHATIC)BENZAMIDES Szmuszkovicz US Patent 4,098, 904 Jul. 4, 1978 Example 23A

Benzeneacetamide amines: structurally novel non-mµ opioids J. Szmuszkovicz, and P.F. Von Voigtlander Journal of Medicinal Chemistry 1982, 25 (10), 1125–1126 DOI: 10.1021/jm00352a005

Factors affecting binding of trans-N-[2-(methylamino)cyclohexyl]benzamides at the primary morphine receptor B.V. Cheney, J. Szmuszkovicz, R.A. Lahti and D.A. Zichi Journal of Medicinal Chemistry 1985, 28 (12), 1853–1864 DOI: 10.1021/jm00150a017

Single stereoisomer analogs in the U-47700 series:

Tom Hsu, Jayapal Reddy Mallareddy, Kayla Yoshida, Vincent Bustamante, Tim Lee, John L. Krstenansky, Alexander C. Zambon, Synthesis and pharmacological characterization of ethylenediamine synthetic opioids in human  $\mu$ -opiate receptor 1 (OPRM1) expressing cells. Pharmacol. Research & Perspectives 7: e00511 (2019) doi: 10.1002/prp2.511

### 5. ACKNOWLEDGEMENT

These data are from a project supported by Award No. 2016-R2-CX-0059, awarded by the National Institute of Justice, Office of Justice Programs, U.S. Department of Justice. The opinions, findings, and conclusions or recommendations expressed in this publication are those of the authors and do not necessarily reflect those of the Department of Justice. We also thank Rigaku Corporation for the loan of the Progeny 1064 Raman instrument.